On the heels of reporting its highest ever end-of-year results for revenue and profit, Almac Group, the global contract pharmaceutical development and manufacturing organization (CDMO), has unveiled a $250 million global capital investment plan to meet increased client demand over the next three years. Investment will take place in existing Almac locations in the UK, Europe, North America and Asia.  “Almac is committed to re-investing all profits back into the business to ensure we are market...